BioNTech SE

Youtube Subscribe

Open: 97.3 Close: 97.48 Change: 0.18

What an AI can tell you about BioNTech SE Stock before investing.

Are looking for the most relevant information about BioNTech SE? Investor spend a lot of time searching for information to make investment decisions in BioNTech SE. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about BioNTech SE are: BioNTech, SE, security, lawsuit, BNTX, October, market, and the most common words in the summary are: biontech, stock, news, republic, se, top, class, . One of the sentences in the summary was: The current trend is considered strongly bearish.. Other searches related to …

Concept Map

Semantic Network

Stock Summary

BioNTech SE develops and commercializes immunotherapies for cancer and other infectious diseases. FixVac product candidates are in Phase II clinical trials for advanced melanoma, including BNT111, BNT112, BN111.

Today's Summary

The BioNTech SE ADR BNTX slipped 1.98% to $97.60 Wednesday, on what proved to be an all-around poor trading session for the stock market. Levi & Korsinsky is seeking to recover losses of shareholders who were adversely affected by alleged securities fraud between March 30, 2022 and October 13, 2023. The current trend is considered strongly bearish.

Today's News

biontech se adr falls thursday, underperforms market - marketwatch.com. The BioNTech SE ADR BNTX, -0.12% slid 0.07% to $97.53 Thursday, on what proved to be an all-around great trading session for the stock market. biontech se adr falls wed Wednesday, underperforms market - marketwatch.com. The BioNTech SE ADR BNTX slipped 1.98% to $97.60 Wednesday, on what proved to be an all-around poor trading session for the stock market. Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: ASRT) between March 30, 2022 and October 13, 2023, inclusive (the “Class Period’s) Deadline to File a Lead Plaintiff Motion has been established, and 2nd to join deepest separation smell,[ Connect WuXi Biologics said it has signed a research agreement with BioNTech for the discovery of monoclonal antibodies for potential development into therapeutic products. Levi & Korsinsky is seeking to recover losses of shareholders who were adversely affected by alleged securities fraud between March 30, 2022 and October 13, 2022. Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed against BioNTech SE (NASDAQ: BNTX) The lawsuit claims defendants made materially false and misleading statements regarding the companys business, operations and prospects. If you purchased BioNTech securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. Levi & Korsinsky is pursuing class action lawsuit against BioNTech SE. The lawsuit seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between March 30, 2022 and October 13, 2023. The current BioNTech SE [ BNTX ] share price is $97.53 USD today. The current trend is considered strongly bearish and is experiencing slight buying pressure. BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases. On Monday, October 16, 2023, during pre-market hours, BioNTec issued a press release announcing that, as a result of Pfizers inventory write-offs and other charges related to Comirnaty. Shareholders of BioNTech SE (NASDAQ:BNTX) received a class action lawsuit against the company and certain of its officers. The Gross Law Firm Notifies Shareholders. Shareholders who were adversely affected by alleged securities fraud between March 30, 2022 and October 13, 2023. Levi & Korsinsky Pursuing Class Action Lawsuit against BioNTech SE (BNTX)

Stock Profile

"BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany."

Keywords

The game is changing. There is a new strategy to evaluate BioNTech SE fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about BioNTech SE are: BioNTech, SE, security, lawsuit, BNTX, October, market, and the most common words in the summary are: biontech, stock, news, republic, se, top, class, . One of the sentences in the summary was: The current trend is considered strongly bearish.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #biontech #stock #news #republic #se #top #class.

Read more →

Youtube Subscribe

---